Systemic inflammation and cardiac surgery: an update

Asimakopoulos, G.
September 2001
Perfusion;Sep2001, Vol. 16 Issue 5, p353
Academic Journal
Cardiac surgery with cardiopulmonary bypass (CPB) is associated with the development of a systemic inflammatory response that can often lead to dysfunction of major organs. The systemic inflammation can be assessed intra- and postoperatively by measuring concentrations of inflammatory mediators in plasma and tissues. These concentrations, however, do not always correlate with the degree of observed organ dysfunction. Various strategies have been used to reduce inflammatory phenomena in patients undergoing CPB. Cardiac surgery without CPB has been performed increasingly with satisfactory results over the past few years. Attenuation of systemic inflammation and improved outcome in high risk patients are potential benefits of this technique. The emergence and expanding performance of cardiac surgical procedures without the use of CPB has given us an excellent tool to investigate the relative importance of CPB as a cause of systemic inflammation. Aprotinin is a protease inhibitor which is used in cardiac surgical patients for its haemostatic effects. Aprotinin has anti-inflammatory properties, the nature of which have not been completely clarified. This article presents a summary of the published literature investigating inflammatory response and organ dysfunction in patients who have cardiac surgery without CPB. It also presents an overview of recent data on the anti-inflammatory action mechanisms of aprotinin.


Related Articles

  • Aprotinin: An Update of its Pharmacology and Therapeutic Use in Open Heart Surgery and Coronary Artery Bypass Surgery. Peters, D.C.; Noble, S. // Drugs;Feb1999, Vol. 57 Issue 2, p233 

    Cardiopulmonary bypass (CPB) is associated with defective haemostasis which results in bleeding and the requirement for allogenic blood product transfusions in many patients undergoing open heart surgery (OHS) and/or coronary artery bypass graft surgery (CABG) with CPB. Conservation of blood has...

  • Bacterial lipopolysaccharide-stimulated release of tumor necrosis factor-alpha from the isolated rat heart: the effect of aprotinin and forskolin. McKinney, William; Newman, Walter H.; Webb, Jerry G.; Castresana, Manuel R. // American Surgeon;Feb2003, Vol. 69 Issue 2, p131 

    Aprotinin has been reported to reduce plasma levels of inflammatory cytokines associated with cardiopulmonary bypass (CPB). Because CPB is also associated with elevated levels of bacterial lipopolysaccharide (LPS) and LPS stimulates release of inflammatory cytokines from the heart we tested the...

  • Adjustment of sweep gas flow during cardiopulmonary bypass. Karabulut, Hasan; Toraman, Fevzi; Tarcan, Sümer; Demirhisar, Önder; Alhan, Cem // Perfusion;Sep2002, Vol. 17 Issue 5, p353 

    Cardiopulmonary bypass (CPB) is one of the major tools of cardiac surgery. However, no clear data are available for the ideal value of sweep gas flow to oxygenator during CPB. The aim of this study was to determine the best value for sweep gas flow during CPB. Thirty patients undergoing isolated...

  • Liver function tests and hyperbilirubinemia in adult patients undergoing open heart surgery. Yuksel, Ahmet; Tuydes, Oktay; Minbay, Hakan; Bicer, Murat; Saba, Davit // Journal of Turgut Ozal Medical Center;2016, Vol. 23 Issue 4, p357 

    Aim: The effects of cardiac surgery and cardiopulmonary bypass on postoperative liver function tests and hyperbilirubinemia in adult patients undergoing open heart surgery were studied, and related literature was reviewed and compared with our results. Materials and Methods: Between January 2013...

  • Aprotinin Reduces the Procalcitonin Rise Associated With Complex Cardiac Surgery and Cardiopulmonary Bypass. MARUNA, P.; KLEIN, A. A.; KUNSTÝŘ, J.; PLOCOVÁ, K. M.; MLEJNSKÝ, F.; LINDNER, J. // Physiological Research;2013, Vol. 62 Issue 1, p27 

    Aprotinin, a nonspecific serine protease inhibitor, has been primarily used as a haemostatic drug in cardiac surgery with cardio-pulmonary bypass (CPB). This study investigated the effect of Aprotinin on the post-operative levels of procalcitonin (PCT) and a set of cytokines in patients...

  • The cerebroprotective effects of pentoxifylline and aprotinin during cardiopulmonary bypass in dogs. Durgut, Kadir; Hosgor, Kemalettin; Gormus, Niyazi; Ozergin, Ufuk; Solak, Hasan // Perfusion;Mar2004, Vol. 19 Issue 2, p101 

    The purpose of this study was to investigate the cerebroprotective effects of pentoxifylline (PNX) and aprotinin in dogs using cardiopulmonary bypass (CPB). PNX and aprotinin might be useful in order to reduce postoperative cerebral damage in patients undergoing cardiac surgery with CPB.

  • Using activated clotting time to estimate intraoperative aprotinin concentration. Iwata, Yusuke; Okamura, Toru; Zurakowski, David; Jonas, Richard A. // Perfusion;Nov2009, Vol. 24 Issue 6, p397 

    Background: The use of aprotinin during cardiopulmonary bypass may be associated with renal dysfunction due to renal excretion of excess drug. We hypothesized that the difference between standard celite activated clotting time (ACT), which is prolonged by aprotinin, and kaolin ACT could provide...

  • Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Grassin-Delyle, S.; Tremey, B.; Abe, E.; Fischler, M.; Alvarez, J. C.; Devillier, P.; Urien, S. // BJA: The British Journal of Anaesthesia;Dec2013, Vol. 111 Issue 6, p916 

    Background Interest in antifibrinolytic tranexamic acid (TA) has grown since the widespread removal of aprotinin, but its dosing during cardiac surgery is still debated. The objectives of this study were to investigate the population pharmacokinetics (PK) of TA given with either low- or...

  • Switch from aprotinin to É›-aminocaproic acid: impact on blood loss, transfusion, and clinical outcome in neonates undergoing cardiac surgery. Martin, K.; Gertler, R.; Liermann, H.; Mayr, N. P.; MacGuill, M.; Schreiber, C.; Vogt, M.; Tassani, P.; Wiesner, G. // BJA: The British Journal of Anaesthesia;Dec2011, Vol. 107 Issue 6, p934 

    Background With the withdrawal of aprotinin from worldwide marketing in November 2007, many institutions treating patients at high risk for hyperfibrinolysis had to update their therapeutic protocols. At our institution, the standard was switched from aprotinin to É›-aminocaproic acid (EACA)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics